Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences has released preclinical data of its two lead compounds - Anavex 2-73 and Anavex 1-41 to treat Alzheimer's disease (AD).
Subscribe to our email newsletter
The study of two drugs which are mixed sigma-1 agonists are designed to assess their anti-amnesic and neuroprotective effects.
The study includes a model to which oligomeric amyloid 25-35 fragments are injected into the brain of rodents which mimic AD.
The data showed that Anavex 2-73 and its metabolite Anavex 19-144 protect against amyloid 25-35-induced oxidative stress, measured by lipid peroxidation in hippocampal cells, a key area of the brain associated with learning and memory.
Anavex 1-41 and its metabolite Anavex 2-140 also showed the similar effects, but are not as selective for sigma receptors as Anavex 2-73.
Anavex executive chairman Cameron Durrant said these neuroprotection data may translate into clinical studies as they continue to explore disease-modifying approaches with their family of compounds and the lead small molecule, Anavex 2-73.
"We eagerly await results from the Anavex 2-73 Phase I clinical trial, which is scheduled for completion soon," Durrant said.